2.23
price down icon3.46%   -0.08
after-market After Hours: 2.34 0.11 +4.93%
loading
Cervomed Inc stock is traded at $2.23, with a volume of 151.95K. It is down -3.46% in the last 24 hours and down -4.70% over the past month. CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$2.31
Open:
$2.28
24h Volume:
151.95K
Relative Volume:
0.37
Market Cap:
$18.41M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-0.3981
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
-0.89%
1M Performance:
-4.70%
6M Performance:
-81.71%
1Y Performance:
-73.42%
1-Day Range:
Value
$2.2208
$2.45
1-Week Range:
Value
$2.21
$2.45
52-Week Range:
Value
$1.80
$26.38

Cervomed Inc Stock (CRVO) Company Profile

Name
Name
Cervomed Inc
Name
Phone
(617) 744-4400
Name
Address
20 PARK PLAZA, BOSTON
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
CRVO's Discussions on Twitter

Compare CRVO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CRVO
Cervomed Inc
2.23 18.41M 0 -6.42M -7.45M -5.6013
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
481.16 123.91B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
722.07 78.94B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
657.97 39.98B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
278.25 35.89B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
119.94 28.75B 3.30B -501.07M 1.03B -2.1146

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-17-24 Downgrade H.C. Wainwright Buy → Neutral
Dec-11-24 Downgrade Chardan Capital Markets Buy → Neutral
Dec-11-24 Downgrade Morgan Stanley Overweight → Underweight
Dec-10-24 Downgrade D. Boral Capital Buy → Hold
Dec-06-24 Initiated ROTH MKM Buy
Dec-05-24 Initiated H.C. Wainwright Buy
Sep-18-24 Initiated Chardan Capital Markets Buy
Jul-26-24 Initiated Morgan Stanley Overweight
Feb-15-24 Initiated Canaccord Genuity Buy
Nov-17-20 Downgrade H.C. Wainwright Buy → Neutral
Mar-21-18 Initiated H.C. Wainwright Buy
View All

Cervomed Inc Stock (CRVO) Latest News

pulisher
Feb 04, 2025

Perigon Wealth Management LLC Makes New Investment in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Feb 04, 2025
pulisher
Feb 01, 2025

CervoMed Provides Update on Neflamapimod DLB Program as - GlobeNewswire

Feb 01, 2025
pulisher
Jan 31, 2025

CervoMed reports progress in dementia drug trial - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

CervoMed Updates on Neflamapimod Trials for Dementia - TipRanks

Jan 31, 2025
pulisher
Jan 31, 2025

CervoMed reports progress in dementia drug trial By Investing.com - Investing.com UK

Jan 31, 2025
pulisher
Jan 31, 2025

CervoMed Inc. Provides Update on Neflamapimod DLB Program -January 31, 2025 at 08:00 am EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 29, 2025

CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Major Breakthrough in Lewy Body Dementia Treatment: CervoMed Reveals Game-Changing Clinical Data - StockTitan

Jan 29, 2025
pulisher
Jan 24, 2025

CervoMed Inc. (NASDAQ:CRVO) Stock Holdings Lifted by Barclays PLC - Defense World

Jan 24, 2025
pulisher
Jan 21, 2025

Roth MKM Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN

Jan 21, 2025
pulisher
Jan 19, 2025

CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average Price Target from Analysts - Defense World

Jan 19, 2025
pulisher
Jan 13, 2025

AWM Investment Company, Inc. Reduces Stake in CervoMed Inc - GuruFocus.com

Jan 13, 2025
pulisher
Jan 11, 2025

CervoMed (STU:DP8) Momentum Rank : 8 (As of Jan. 11, 2025) - GuruFocus.com

Jan 11, 2025
pulisher
Jan 09, 2025

Geode Capital Management LLC Raises Holdings in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jan 09, 2025
pulisher
Jan 09, 2025

Barclays PLC Acquires 5,919 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jan 09, 2025
pulisher
Jan 04, 2025

Brookline Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN

Jan 04, 2025
pulisher
Jan 02, 2025

State Street Corp Boosts Stake in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jan 02, 2025
pulisher
Dec 25, 2024

Analysts Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $42.00 - Defense World

Dec 25, 2024
pulisher
Dec 20, 2024

HC Wainwright Brokers Reduce Earnings Estimates for CervoMed - Defense World

Dec 20, 2024
pulisher
Dec 17, 2024

HC Wainwright & Co. Downgrades CervoMed (CRVO) - MSN

Dec 17, 2024
pulisher
Dec 14, 2024

Research Analysts Issue Forecasts for CervoMed Q1 Earnings - Defense World

Dec 14, 2024
pulisher
Dec 13, 2024

CervoMed (NASDAQ:CRVO) Cut to Hold at Brookline Capital Management - Defense World

Dec 13, 2024
pulisher
Dec 12, 2024

CervoMed price target lowered to $4 from $45 at Roth MKM - Yahoo Finance

Dec 12, 2024
pulisher
Dec 12, 2024

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 12, 2024
pulisher
Dec 12, 2024

CervoMed Awards Key Executive Stock Options in Strategic Talent Acquisition Move - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

CervoMed's dementia drug fails mid-stage trial, shares slump - MSN

Dec 12, 2024
pulisher
Dec 11, 2024

Chardan Capital Downgrades CervoMed (CRVO) - MSN

Dec 11, 2024
pulisher
Dec 11, 2024

What Was Behind CervoMed’s Lewy Body Disappointment? - News & Insights

Dec 11, 2024
pulisher
Dec 11, 2024

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint - Yahoo Finance

Dec 11, 2024
pulisher
Dec 11, 2024

Morgan Stanley cuts CervoMed to Underweight on disappointing trial results By Investing.com - Investing.com UK

Dec 11, 2024
pulisher
Dec 10, 2024

CervoMed stock downgraded to Hold as Phase 2b trial disappoints By Investing.com - Investing.com Canada

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed shares rating downgraded after trial data disappoints - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

Jones Trading Downgrades CervoMed (CRVO) - MSN

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed's dementia drug fails to meet mid-stage trial goals - MSN

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed stock downgraded to Hold as Phase 2b trial disappoints - Investing.com

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed shares rating downgraded after trial data disappoints By Investing.com - Investing.com Canada

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MSN

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Yahoo Finance

Dec 10, 2024
pulisher
Dec 10, 2024

US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed Shares Slide to All-Time Low After Study Failure - MarketWatch

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed’s dementia drug fails to meet mid-stage trial goals - 1470 & 100.3 WMBD

Dec 10, 2024
pulisher
Dec 10, 2024

Late-stage plans on ice as CervoMed's oral drug fails dementia study - FirstWord Pharma

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial - Fierce Biotech

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed Inc. Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies - Marketscreener.com

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed tumbles after dementia drug fails to meet mid-stage trial goals - XM

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed Faces Setback in Phase 2b Trial - TipRanks

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints - MarketWatch

Dec 10, 2024
pulisher
Dec 10, 2024

CervoMed Announces Topline Data from RewinD-LB Phase 2b - GlobeNewswire

Dec 10, 2024
pulisher
Dec 09, 2024

HC Wainwright Predicts CervoMed FY2024 Earnings - MarketBeat

Dec 09, 2024
pulisher
Dec 08, 2024

CervoMed (NASDAQ:CRVO) Research Coverage Started at HC Wainwright - Defense World

Dec 08, 2024
pulisher
Dec 08, 2024

CervoMed (NASDAQ:CRVO) Coverage Initiated at Roth Mkm - Defense World

Dec 08, 2024

Cervomed Inc Stock (CRVO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$80.78
price down icon 0.82%
$20.67
price down icon 0.53%
$353.75
price down icon 0.12%
$5.04
price down icon 2.14%
biotechnology ONC
$228.87
price up icon 0.53%
$119.94
price down icon 1.99%
Cap:     |  Volume (24h):